Polycystic Ovary Syndrome (PCOS) has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), marking a significant global shift in how the condition is understood, diagnosed, and treated.
Published on 12 May 2026 in The Lancet, the updated terminology reflects findings from a 14-year international consensus involving over 14,000 patients and healthcare professionals. The change repositions the condition from a primarily reproductive disorder to a systemic hormonal and metabolic disease affecting multiple organs and regulatory systems in the body.
The previous name, Polycystic Ovary Syndrome, has long been criticized for being misleading. Despite its name, the “cysts” associated with the condition are not true cysts but underdeveloped follicles caused by hormonal imbalance. In addition, many individuals experience symptoms even without visible ovarian cysts, while others may have cysts without the broader metabolic or endocrine features of the condition.
Under the new definition, PMOS is understood through three core systems:
- Polyendocrine: Highlighting disruptions across multiple hormonal pathways, including adrenal and neurological signalling systems, not just reproductive hormones.
- Metabolic: Recognising insulin resistance, weight regulation challenges, and increased risks of Type 2 diabetes and cardiovascular disease as central components of the condition.
- Ovarian: Retaining the reproductive aspect but placing it within a broader systemic framework.
Health experts say the renaming is expected to improve diagnosis timelines, which can currently take up to 12 years in some cases, while also increasing awareness of associated mental health impacts such as anxiety and depression.
According to Professor Helena Teede, the updated terminology was designed with patient benefit, scientific accuracy, and reduced stigma in mind, ensuring clearer communication and more holistic care approaches moving forward.
Implementation of the PMOS terminology will roll out gradually, with full integration into global clinical guidelines expected by 2028.
Comments are closed.